» Articles » PMID: 15647284

LIM-kinase 2 and Cofilin Phosphorylation Mediate Actin Cytoskeleton Reorganization Induced by Transforming Growth Factor-beta

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Jan 14
PMID 15647284
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Reorganization of the actin cytoskeleton in response to growth factor signaling, such as transforming growth factor beta (TGF-beta), controls cell adhesion, motility, and growth of diverse cell types. In Swiss3T3 fibroblasts, a widely used model for studies of actin reorganization, TGF-beta1 induced rapid actin polymerization into stress fibers and concomitantly activated RhoA and RhoB small GTPases. Consequently, dominant-negative RhoA and RhoB mutants blocked TGF-beta1-induced actin reorganization. Because Rho GTPases are known to regulate the activity of LIM-kinases (LIMK), we found that TGF-beta1 induced LIMK2 phosphorylation with similar kinetics to Rho activation. Cofilin and LIMK2 co-precipitated and cofilin became phosphorylated in response to TGF-beta1, whereas RNA interference against LIMK2 blocked formation of new stress fibers by TGF-beta1. Because the kinase ROCK1 links Rho GTPases to LIMK2, we found that inhibiting ROCK1 activity blocked completely TGF-beta1-induced LIMK2/cofilin phosphorylation and downstream stress fiber formation. We then tested whether the canonical TGF-beta receptor/Smad pathway mediates regulation of the above effectors and actin reorganization. Adenoviruses expressing constitutively activated TGF-beta type I receptor led to robust actin reorganization and Rho activation, whereas the constitutively activated TGF-beta type I receptor with mutated Smad docking sites (L45 loop) did not affect either actin organization or Rho activity. In line with this, ectopic expression of the inhibitory Smad7 inhibited TGF-beta1-induced Rho activation and cytoskeletal reorganization. Our data define a novel pathway emanating from the TGF-beta type I receptor and leading to regulation of actin assembly, via the kinase LIMK2.

Citing Articles

Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.

Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.

PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.


LIM kinases in cardiovascular health and disease.

Lateef O, Foote C, Power G, Manrique-Acevedo C, Padilla J, Martinez-Lemus L Front Physiol. 2025; 15():1506356.

PMID: 39744707 PMC: 11688343. DOI: 10.3389/fphys.2024.1506356.


TGF-β2 enhances nanoscale cortex stiffness via condensation of cytoskeleton-focal adhesion plaque.

Duan M, Liu Y, Pi C, Zhao Y, Tian Y, Xie J Biophys J. 2024; 124(2):336-350.

PMID: 39645584 PMC: 11788479. DOI: 10.1016/j.bpj.2024.12.007.


TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.


Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells.

Zheng B, Sun X, Zhang L, Qu G, Ren C, Yan P Braz J Med Biol Res. 2024; 57:e13152.

PMID: 38381883 PMC: 10880891. DOI: 10.1590/1414-431X2023e13152.